110 related articles for article (PubMed ID: 22118048)
1. Pharmacogenomics of cytarabine in childhood leukemia.
Lamba JK
Pharmacogenomics; 2011 Dec; 12(12):1629-32. PubMed ID: 22118048
[No Abstract] [Full Text] [Related]
2. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
3. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
4. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
5. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.
Anderson JT; Hu S; Fu Q; Baker SD; Sparreboom A
Pharmacol Res Perspect; 2019 Dec; 7(6):e00534. PubMed ID: 31832201
[TBL] [Abstract][Full Text] [Related]
6. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
8. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
9. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
[TBL] [Abstract][Full Text] [Related]
10. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
[TBL] [Abstract][Full Text] [Related]
11. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Lamba JK; Crews KR; Pounds SB; Cao X; Gandhi V; Plunkett W; Razzouk BI; Lamba V; Baker SD; Raimondi SC; Campana D; Pui CH; Downing JR; Rubnitz JE; Ribeiro RC
Pharmacogenomics; 2011 Mar; 12(3):327-39. PubMed ID: 21449673
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
13. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
[TBL] [Abstract][Full Text] [Related]
14. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
15. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
[TBL] [Abstract][Full Text] [Related]
16. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.
Cai J; Damaraju VL; Groulx N; Mowles D; Peng Y; Robins MJ; Cass CE; Gros P
Cancer Res; 2008 Apr; 68(7):2349-57. PubMed ID: 18381442
[TBL] [Abstract][Full Text] [Related]
17. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
[No Abstract] [Full Text] [Related]
18. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.
Macanas-Pirard P; Leisewitz A; Broekhuizen R; Cautivo K; Barriga FM; Leisewitz F; Gidi V; Riquelme E; Montecinos VP; Swett P; Besa P; Ramirez P; Ocqueteau M; Kalergis AM; Holt M; Rettig M; DiPersio JF; Nervi B
PLoS One; 2012; 7(5):e37203. PubMed ID: 22629369
[TBL] [Abstract][Full Text] [Related]
19. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
Jordheim LP; Nguyen-Dumont T; Thomas X; Dumontet C; Tavtigian SV
Drug Metab Dispos; 2008 Dec; 36(12):2419-23. PubMed ID: 18775979
[TBL] [Abstract][Full Text] [Related]
20. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
